NUVALENT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.86 USD | +1.20% |
|
+6.53% | -9.15% |
| Apr. 17 | Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing | MT |
| Apr. 17 | Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target | MT |
Chart calendar Nuvalent, Inc.
b2d354fc0f6618f14fd39034c6652535.nwjVQF39Ri9om2i4vpqZeVuGcBlLeOGPI4t6J3aC5sY.53GZEWu-Plwpzi6Nh8nJPg_KEyl_TdDXc90UEg721qPMO70YFp8fTlzKPQ~ef97800cc6e64eb260465e3e08e287ff
Upcoming events on Nuvalent, Inc.
Past events on Nuvalent, Inc.
| 2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract No. LB182 |
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Abstract No. 1979 |
| 2024-03-12 08:00 am | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 2024-03-06 01:30 pm | TD Cowen Health Care Conference - Fireside Chat |
| 2024-02-27 06:30 am | Q4 2023 Earnings Release |
| 2024-02-08 10:30 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-01-09 10:30 am | JPMorgan Healthcare Conference |
| 2023-11-29 01:00 pm | Piper Sandler Healthcare Conference |
| 2023-11-15 03:00 pm | Stifel Healthcare Conference |
| 2023-11-14 06:30 am | Q3 2023 Earnings Release |
| 2023-11-08 01:00 pm | BMO BioPharma Spotlight Series: Oncology |
| 2023-10-13 12:30 pm | AACR-NCI-EORTC ANE Symposium - Abstract Number: 35177 |
| 2023-10-13 08:00 am | AACR NCI EORTC Symposium |
| 2023-09-13 08:50 am | Morgan Stanley Global Healthcare Conference |
| 2023-09-08 10:15 am | Wells Fargo Healthcare Conference |
| 2023-08-10 06:30 am | Q2 2023 Earnings Release |
| 2023-08-09 08:00 am | Canaccord Genuity Growth Conference |
| 2023-08-07 | Wedbush PacGrow Healthcare Conference |
| 2023-06-14 | Annual General Meeting |
| 2023-05-31 10:30 am | TD Cowen Oncology Innovation Summit |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -45,8 -43,4 -5.69% | -86,1 -78,1 -10.25% | -149 -144 -4.11% | -207 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -45,8 -43,6 -5.17% | -86,1 -79,9 -7.75% | -149 -144 -3.85% | -201 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -46,3 -44,2 -4.92% | -81,9 -78,1 -4.76% | -126 -124 -1.53% | -176 |
|
Net income Million USD | Released Forecast Spread | -14,6 | -46,3 -43,9 -5.45% | -81,9 -78,2 -4.64% | -126 -125 -0.65% | -185 |
|
EPS USD | Released Forecast Spread | -0,94 | -2,13 -1,81 -17.95% | -1,65 -1,56 -5.56% | -2,17 -2,15 -1.04% | -2,91 |
| Announcement Date | 28/05/21 | 29/03/22 | 16/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -17,4 -15,0 -15.85% | -17,7 -21,0 15.77% | -18,7 -21,0 10.8% | -20,4 -22,0 7.33% | -29,3 -21,0 -39.52% | -30,2 -32,0 5.59% | -34,1 -31,0 -9.88% | -38,8 -36,0 -7.73% | -46,4 -41,0 -13.26% | -48,0 | -51,0 | -53,0 | -55,0 | |
|
EBIT Million USD | Released Forecast Spread | -17,4 -15,2 -14.58% | -17,7 -19,4 8.82% | -18,7 -20,5 8.62% | -20,4 -22,1 7.75% | -29,3 -22,8 -28.72% | -30,2 -30,9 2.1% | -34,1 -33,0 -3.34% | -38,8 -36,6 -5.99% | -46,4 -40,9 -13.41% | -46,6 | -48,9 | -51,0 | -53,3 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -17,3 -15,2 -14.12% | -17,5 -19,4 9.4% | -18,5 -20,5 9.72% | -19,7 -21,7 9.05% | -26,1 -22,6 -15.62% | -25,2 -29,3 13.91% | -29,1 -30,0 3.03% | -33,6 -33,3 -0.97% | -38,3 -37,0 -3.54% | -41,0 | -43,0 | -45,2 | -47,3 | |
|
Net income Million USD | Released Forecast Spread | -17,3 -15,2 -14.12% | -17,5 -19,4 9.4% | -18,5 -20,5 9.72% | -19,7 -21,7 9.05% | -26,1 -22,6 -15.62% | -25,2 -29,3 13.91% | -29,1 -30,5 4.62% | -33,6 -34,0 0.93% | -38,3 -37,8 -1.38% | -42,4 | -44,6 | -46,9 | -49,3 | |
|
EPS USD | Released Forecast Spread | -0,36 -0,32 -11.77% | -0,36 -0,40 8.92% | -0,38 -0,41 7.88% | -0,41 -0,44 6.46% | -0,49 -0,42 -16.95% | -0,44 -0,51 13.99% | -0,51 -0,53 4.59% | -0,59 -0,58 -1.21% | -0,62 -0,60 -3.07% | -0,67 | -0,70 | -0,75 | -0,79 | -0,75 |
| Announcement Date | 29/03/22 | 12/05/22 | 10/08/22 | 10/11/22 | 16/03/23 | 11/05/23 | 10/08/23 | 14/11/23 | 27/02/24 | - | - | - | - | - |
More events
Past sector events for Nuvalent, Inc.
| 2024-04-26 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-26 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-26 01:00 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 2024-04-25 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-25 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-25 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-25 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-25 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-25 07:00 am | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 2024-04-25 02:00 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NUVL Stock
- Calendar Nuvalent, Inc.
